Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Manetti

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Current Cancer Drug Targets|March 15, 2012
Recent findings confirm LIM domain kinases as emerging target candidates for cancer therapyF Manetti
Current Medicinal Chemistry|September 5, 2015
Targeting the Hedgehog Signaling Pathway with Small Molecules from Natural SourcesE Petricci, F Manetti
Mini Reviews in Medicinal Chemistry|February 20, 2007
Last findings on dual inhibitors of abl and SRC tyrosine-kinasesS Schenone, F Manetti, M Botta
Current Pharmaceutical Design|December 5, 2000
Fibroblast growth factors and their inhibitorsM Botta, F Manetti, F Corelli
Current Pharmaceutical Design|July 14, 2007
SRC inhibitors and angiogenesisS Schenone, F Manetti, M Botta
Minerva Cardioangiologica|April 1, 1989
[Clinical indications for performing Doppler ultrasonography of the extracranial carotid vessels. A series of 805 subjects]C F Manetti, F Zacà, T Bombardini
Mini Reviews in Medicinal Chemistry|February 3, 2007
New derivatives of BM212: A class of antimycobacterial compounds based on the pyrrole ring as a scaffoldM Biava, G C Porretta, F Manetti
La Radiologia Medica|July 22, 1999
[Assessment of potential exposure risk for radiotherapy staff working with lineal accelerators]A Tofani, A Del Corona, F Manetti
Current Medicinal Chemistry|June 8, 2002
Arylpiperazines with affinity toward alpha(1)-adrenergic receptorsF Manetti, F Corelli, G Strappaghetti, et al.
Biochimica Et Biophysica Acta|August 15, 1996
Probing the substrate specificity for lipases. A CoMFA approach for predicting the hydrolysis rates of 2-arylpropionic esters catalyzed by Candida rugosa lipaseM Botta, E Cernia, F Corelli, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Current Cancer Drug Targets|March 15, 2012
Recent findings confirm LIM domain kinases as emerging target candidates for cancer therapyF Manetti
Current Medicinal Chemistry|September 5, 2015
Targeting the Hedgehog Signaling Pathway with Small Molecules from Natural SourcesE Petricci, F Manetti
Mini Reviews in Medicinal Chemistry|February 20, 2007
Last findings on dual inhibitors of abl and SRC tyrosine-kinasesS Schenone, F Manetti, M Botta
Current Pharmaceutical Design|December 5, 2000
Fibroblast growth factors and their inhibitorsM Botta, F Manetti, F Corelli
Current Pharmaceutical Design|July 14, 2007
SRC inhibitors and angiogenesisS Schenone, F Manetti, M Botta
Minerva Cardioangiologica|April 1, 1989
[Clinical indications for performing Doppler ultrasonography of the extracranial carotid vessels. A series of 805 subjects]C F Manetti, F Zacà, T Bombardini
Mini Reviews in Medicinal Chemistry|February 3, 2007
New derivatives of BM212: A class of antimycobacterial compounds based on the pyrrole ring as a scaffoldM Biava, G C Porretta, F Manetti
La Radiologia Medica|July 22, 1999
[Assessment of potential exposure risk for radiotherapy staff working with lineal accelerators]A Tofani, A Del Corona, F Manetti
Current Medicinal Chemistry|June 8, 2002
Arylpiperazines with affinity toward alpha(1)-adrenergic receptorsF Manetti, F Corelli, G Strappaghetti, et al.
Biochimica Et Biophysica Acta|August 15, 1996
Probing the substrate specificity for lipases. A CoMFA approach for predicting the hydrolysis rates of 2-arylpropionic esters catalyzed by Candida rugosa lipaseM Botta, E Cernia, F Corelli, et al.
Pageof 3